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Dengue virus belongs to family Flaviviridae, having four serotypes that spread by the bite of infected 
Aedes mosquitoes. It causes a wide spectrum of illness from mild asymptomatic illness to severe fatal 
dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Approximately 2.5 billion people live 
in dengue-risk regions with about 100 million new cases each year worldwide. The cumulative dengue 
diseases burden has attained an unprecedented proportion in recent times with sharp increase in the 
size of human population at risk. Dengue disease presents highly complex pathophysiological, economic 
and ecologic problems. In India, the first epidemic of clinical dengue-like illness was recorded in Madras 
(now Chennai) in 1780 and the first virologically proved epidemic of dengue fever (DF) occurred in 
Calcutta (now Kolkata) and Eastern Coast of India in 1963-1964. During the last 50 years a large number 
of physicians have treated and described dengue disease in India, but the scientific studies addressing 
various problems of dengue disease have been carried out at limited number of centres. Achievements 
of Indian scientists are considerable; however, a lot remain to be achieved for creating an impact. This 
paper briefly reviews the extent of work done by various groups of scientists in this country.
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Introduction
 Dengue is an acute viral infection with potential 
fatal complications. Dengue fever was first referred as 
“water poison” associated with flying insects in a 
Chinese medical encyclopedia in 992 from the Jin 
Dynasty (265-420 AD). The word “dengue” is derived 
from the Swahili phrase Ka-dinga pepo, meaning 
“cramp-like seizure”. The first clinically recognized 
dengue epidemics occurred almost simultaneously in 
Asia, Africa, and North America in the 1780s. The first 
clinical case report dates from 1789 of 1780 epidemic 
in Philadelphia is by Benjamin Rush, who coined the 
term “break bone fever” because of the symptoms of 
myalgia and arthralgia (quoted from www.
globalmedicine.nl/index.php/dengue-fever). The 
term dengue fever came into general use only after 
1828. Dengue viruses (DV) belong to family 
Flaviviridae and there are four serotypes of the virus 
referred to as DV-1, DV-2, DV-3 and DV-4. DV is a 
positive-stranded encapsulated RNA virus and is 
composed of three structural protein genes, which 
encode the nucleocapsid or core (C) protein, a 
membrane-associated (M) protein, an enveloped (E) 
glycoprotein and seven non-structural (NS) proteins. It 
is transmitted mainly by Aedes aegypti mosquito and 
also by Ae. albopictus. All four serotypes can cause the 
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full spectrum of disease from a subclinical infection to 
a mild self limiting disease, the dengue fever (DF) and 
a severe disease that may be fatal, the dengue 
haemorrhagic fever/dengue shock syndrome (DHF/
DSS). The WHO 2009 classification divides dengue 
fever into two groups: uncomplicated and severe1, 
though the 1997 WHO classification is still widely 
used2. The 1997 classification divided dengue into 
undifferentiated fever, dengue fever (DF), and dengue 
haemorrhagic fever (DHF)1. Four main characteristic 
manifestations of dengue illness are (i) continuous high 
fever lasting 2-7 days; (ii) haemorrhagic tendency as 
shown by a positive tourniquet test, petechiae or 
epistaxis; (iii) thrombocytopoenia (platelet count 
<100x109/l); and (iv) evidence of plasma leakage 
manifested by haemoconcentration (an increase in 
haematocrit 20% above average for age, sex and 
population), pleural effusion and ascites, etc. Excellent 
work has been done at some of the centres in India on 
molecular epidemiology of dengue immunopathology 
and vaccine development. This paper reviews the work 
done in this country. The key words “dengue/India” 
reflected 784 papers in PubMed. Only some of the 
representative papers could be cited here due to 
constraint of space.
History
 Dengue virus was isolated in Japan in 1943 by 
inoculation of serum of patients in suckling mice3 and 
at Calcutta (now Kolkata) in 1944 from serum samples 
of US soldiers4. The first epidemic of clinical dengue-
like illness was recorded in Madras (now Chennai) in 
1780 and the first virologically proved epidemic of 
DF in India occurred in Calcutta and Eastern Coast of 
India in 1963-19645-7. The first major epidemic of the 
DHF occurred in 1953-1954 in Philippines followed 
by a quick global spread of epidemics of DF/DHF8. 
DHF was occurring in the adjoining countries but it 
was absent in India for unknown reasons as all the risk 
factors were present. The DHF started simmering in 
various parts of India since 19889-11. The first major 
wide spread epidemics of DHF/DSS occurred in India 
in 1996 involving areas around Delhi12 and Lucknow13 
and then it spread to all over the country14.
Epidemiology of dengue
 The epidemiology of dengue fevers in the 
Indian subcontinent has been very complex and has 
substantially changed over almost past six decades 
in terms of prevalent strains, affected geographical 
locations and severity of disease. The very first report 
of existence of dengue fevers in India was way back 
in 194615. Thereafter, for the next 18 years, there was 
no significant dengue activity reported anywhere in the 
country. In 1963-1964, an initial epidemic of dengue 
fever was reported on the Eastern Coast of India7,16-20, 
it spread northwards and reached Delhi in 196721 and 
Kanpur in 196822,23. Simultaneously it also involved the 
southern part of the country24, 25 and gradually the whole 
country was involved with wide spread epidemics 
followed by endemic/hyperendemic prevalence of all 
the four serotypes of DV. The epidemiology of dengue 
virus and its prevalent serotypes has been ever changing. 
The epidemic at Kanpur during 1968 was due to DV-422 
and during 1969 epidemic, both DV-2 and DV-4 were 
isolated26. It was completely replaced by DV-2 during 
1970 epidemic in the adjoining city of Hardoi27. Myers 
et al24, 28 had reported the presence of DV-3 in patients 
and Ae. aegypti at Vellore during the epidemic of 1966 
while during the epidemic of 1968, all the four types 
of DV were isolated from patients and mosquitoes29. In 
another study Myers & Varkey30 reported an instance 
of a third attack of DV in one individual. DV-2 was 
isolated during the epidemics of dengue in urban and 
rural areas of Gujarat State during 1988 and 198931. 
Outbreaks of dengue occurred in Rajasthan by DV- 
1 and DV-332, DV-333, Madhya Pradesh by DV-334, 
Gujarat by DV-231 and in Haryana by DV-235. DV-2 
was the predominant serotype circulating in northern 
India, including Delhi, Lucknow and Gwalior12,13,36 
while DV-1 was isolated during the 1997 epidemic at 
Delhi37. The phylogenetic analysis by the Molecular 
Evolutionary Genetics Analysis programme suggests 
that the 1996 Delhi isolates of DV-2 were genotype IV. 
The 1967 isolate was similar to a 1957 isolate of DV-2, 
from India, and was classified as genotype V. This 
study indicates that earlier DV-2 strains of genotype 
V have been replaced by genotype IV38. The Gwalior 
DV-2 viruses were classified into genotype-IV, and 
were most closely related to Delhi 1996 DV-2 viruses 
and FJ 10/11 strains prevalent in the Fujian State of 
China. However, two earlier Indian isolates of DV-2 
were classified into genotype-V. Genotype V of DV-2 
has been replaced by genotype IV during the past 
decade, which continues to circulate silently in north 
India, and has the potential to re-emerge and cause 
major epidemics of DF and DHF39. DV-2 has also been 
reported from southern India - in Kerala alongwith 
DV-340.
 DV-3 has been isolated during the epidemics 
at Vellore in 196624,28, at Calcutta in 198341 and in 
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199010, at Jalore city, Rajasthan in 198533 at Gwalior 
in 2003 and 200442,43 and at Tirupur, Tamil Nadu in 
201044. Phylogenetic analysis showed that the Madurai 
isolates were closely related to Gwalior and Delhi 
isolates. The emergence of DV-4 has been reported 
in Andhra Pradesh45 and Pune, Maharashtra46, which 
was also implicated in increased severity of disease. 
At Delhi, till 2003, the predominant serotype was 
DV-2 (genotype IV) but in 2003 for the first time all 
four dengue virus subtypes were found to co-circulate 
in Delhi thus changing it to a hyperendemic state47 
followed by complete predominance of DV serotype 
3 in 200548. During the 2004 epidemic of DHF/DSS in 
northern India a sudden shift and dominance of the DV 
serotype-3 (subtype III) occurred replacing the earlier 
circulating serotype-2 (subtype IV)43. Co-circulation 
of DV serotypes in Delhi in 2003-2004 has also been 
reported43, which may have implications for increased 
DHF/DSS. Emergence of a distinct lineage of DV-1, 
having similarity with the Comoros/Singapore 1993 
and Delhi 1982 strains, but quite different from the 
Delhi 2005 lineage and microevolution of the pre-
circulating DV-3 has been reported49. Co-circulation 
of several serotypes of dengue viruses has resulted in 
concurrent infection in some patients with multiple 
serotypes of DV50. Further, replacement of DV-2 and 3 
with DV-1 as the predominant serotype in Delhi over a 
period of three years (2007-2009) has been reported51. 
Concurrent infection by Chikungunya and DV-2 was 
reported from Vellore52 and Delhi53 (Table I).
Dengue virus and its serotypes
 DV-1 was isolated in 1956 at Vellore. All the Indian 
DV-1 isolates belong to the American African (AMAF) 
genotype. The Indian DV-1 isolates are distributed into 
four lineages, India I, II, III and the Africa lineage. 
Of these, India III is the oldest and extinct lineage; 
the Afro-India is a transient lineage while India I is 
imported from Singapore and India II, evolving in situ, 
are the circulating lineages75. The American genotype 
of DV-2 which circulated predominantly in India during 
the pre-1971 period, was subsequently replaced by the 
Cosmopolitan genotype. Post-1971 Indian isolates 
formed a separate subclade within the Cosmopolitan 
genotype. DV-2 strains were isolated in India over 
a time span of more than 50 years (1956-2011). The 
re-emergence of an epidemic strain of DV type-3 in 
Delhi in 2003 and its persistence in subsequent years 
marked a changing trend in DV circulation in this part 
of India49. Occasional reports of circulation of DV-4 
are also seen, though it is not the predominant type in 
India76,47. 
Clinical presentation
 The classical clinical presentation of dengue virus 
infection has been observed in the country, however, 
several atypical clinical presentations have also been 
reported (Table II). 
Experimental studies on immune response and 
pathogenesis in DV infection
 Extensive studies have been carried out in mouse to 
understand the immune response and the mechanisms of 
immunosuppression and pathogenesis of severe dengue 
disease. DV induces mainly humoral immune response 
while the delayed type hypersensitivity response is poor. 
DV-infected sick mice develop immunosuppression, 
both to homologous and heterologous antigens104-106. 
Macrophages process DV antigen by serine proteases 
and present it to B cells in vitro and in vivo, leading to 
their clonal expansion107-110.
DV-specific follicular helper T cells (ThF)
 DV induces generation of helper T cells (ThF) in 
mouse spleen which enhance clonal expansion of DV-
specific B cells111 (Table III). DV-specific ThF secrete a 
cytokine, the helper factor (HF)112 which is composed 
of two chains, one has antigen and the other has I-A 
determinants; both chains are essential for helper 
activity113. The helper signal is transmitted only by a 
close physical contact of the plasma membranes of B 
cells and ThF or HF-adsorbed macrophage. ThF and 
HF help in production of DV-specific antibodies115,116.
T cells producing cytotoxic factor (TCF) 
 Cytotoxic factor (CF), a unique cytokine, is 
produced by CD4+ T cells in DV infected mice and 
man. CF has no homology with any of the known 
proteins in their amino-terminal sequence134. Most of 
the patients with dengue virus infection have CF in 
their sera, with peak amounts in the most severe cases 
of DHF136,139. CD4+ T cells and H-2A- macrophages are 
killed by CF while it induces H-2A+ macrophage to 
produce another cytokine, the macrophage cytotoxin 
(CF2) which amplifies the effect of CF, thus producing 
immunosuppression to heterologous antigens106. CF 
appears in the serum before the clinical illness and is 
present in 100 per cent patients with DF/DHF up to day 
4 of illness, detectable up to day 20 of illness139. CF is 
produced in ex vivo cultures of CD4+ T cells obtained 
from peripheral blood of the patients with severe 
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Table I. Epidemiological studies where dengue virus was identified
Year Region where study was conducted Type of dengue virus detected Reference
1964 Vellore, Tamil Nadu DV-2 52
NA South India DV-3 24
1966 Vellore, Tamil Nadu DV-3 28
1968 Vellore, Tamil Nadu DV- 1,2,3 & 4 29
1968 Kanpur, Uttar Pradesh DV-4 22
1969 Kanpur, Uttar Pradesh DV-4 and DV-2 26
1970 Hardoi, Uttar Pradesh DV-2 27
NA NA DV- 1,2,3 & 4 30
1983 Kolkata, West Bengal DV-3 41
1985 Jalore town, South-West Rajasthan DV-3 33
NA Chikalthana, Pimpalgaon and Waloor villages in Parbhani  
district of Maharashtra.
DV-1 & 2 54
1988 Delhi DV-2 9
1990 Calcutta, West Bengal DV-3 10
1988 Rural and urban areas of Gujarat DV-2 31
1993 Mangalore, Karnataka DV-2 55
NA Assam and Nagaland DV-2 56
1996 Ludhiana, Punjab DV- 1,2,3 & 4 57
1996 Lucknow DV-2 13
1996 Delhi DV-2 58, 59
1996 Delhi DV-2 12
1997 Delhi DV-1 60
1996 Delhi DV-2 (Genotype IV) 38
NA Ahmedabad, Gujarat DV-2 61
1997 Delhi DV-1 37
NA Delhi DV-2 (Genotype IV) 62
1996 Rural areas of Haryana DV-2 35
2001 Dharmapuri district, Tamil Nadu DV-2 63
NA Andaman and Nicobar Islands DV-2 64
2001 Gwalior, Madhya Pradesh DV-2 36
NA Northern India DV-2 (Genotype IV) 39
2001 Chennai, Tamil Nadu DV-3 65
2003 Northern India (Delhi & Gwalior) DV-3 42
2005 Kolkata, West Bengal DV-3 66
2003 Kanyakumari district, Tamil Nadu DV-3 67
2003-04 Delhi DV-3 (subtype III) 43
2003-05 Delhi 2003 - DV - 1,2,3 & 4 2005 - D - 3 48
2006 Delhi DV-3 50
2006 Delhi DV-1 & 3 49
2001-07 North India (Delhi and Gwalior region) DV-1 (Genotype III) 68
2006 Delhi DV-1,3 & 4 53
2008 Delhi region DV-1,2 & 3 51
1956-2005 Entire country DV-2 69
2002-06 Delhi DV-1, 2, 3 & 4 70
2003 Delhi DV-3 (Genotype III) 71
2008 Ernakulam, Kerala DV-2 & 3 40
2007 Rural areas of Madurai, Tamil Nadu DV-3 (Genotype III) 72
2007 Andhra Pradesh DV-1 & 4 (Genotype I) 45
2003-08 Different parts of the country DV-3 (Genotype III) 73
2007-09 Delhi DV 1, 2, 3 & 4 74
2009-10 Pune, Maharashtra DV-4 (Genotype I) 46
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Table II. Atypical clinical presentations of dengue virus infection
System/Organ Clinical presentation References
Neurological manifestations Encephalopathy, acute motor weakness, seizures, neuritis, Guillain Barre 
syndrome, hypokalemic paralysis acute viral myositis, acute encephalitis
77-80
Hepatic involvement Acute liver failure, significant mortality, hepatic encephalopathy, 
hepatomegaly epistaxis, jaundice and petechial rashes
81-84
Myositis Acute myositis, pure motor quadriplegia 85- 87
Cardiac involvement Acute reversible cardiac insult, sinoatrial block and atrioventricular 
dissociation
88, 89
Lupus erythematosus (systemic) Abnormal immune response leading to systemic lupus erythematosus 90, 91
Occlusion complications & uveitis Unilateral blurring of inferior visual field 92
Oxidative stress Increase in oxidative stress, significantly elevated PCOs and low PBSH group 
levels
93, 94
Acute renal dysfunction Renal dysfunction, acute kidney injury 95, 96
Acute inflammatory colitis Lower gastrointestinal bleeding and acute inflammatory colitis 97
Cutaneous manifestations Maculopapular/morbilliform eruption followed by ecchymotic, petechial, and 
macular/ scarlatiniform eruption
98
Confluent erythema, morbilliform eruptions, and haemorrhagic lesions 99
Kawasaki disease Young child developed Kawasaki disease later in disease 100
Haemophagocytic syndrome Bone marrow haemophagocytosis associated with nasal bleeding and 
pancytopenia
101-103
PCO, protein carbonyls; PBSH, protein bound sulfhydral group 
Table III. T cell functions in dengue virus infection in mice
T-Cells Cell subtype Cytokine Functions References
T Helper Follicular Helper factor Clonal amplification of DV-specific B cells 112-116
T Suppressor 
(Regulatory T cells)
TS1 Suppressor factor 1 Induction of TS2 117-124
TS2 Suppressor factor 2 Induction of TS3
TS3 Suppressor factor 3 Suppression of DV-specific B cell response 123, 125
T Cytotoxic factor TCF mouse Mouse cytotoxic factor Increase capillary permeability, kill a 
subpopulation of macrophage and CD4 T cells
112, 126-135
TCF human Human cytotoxic factor 135, 136, 138
dengue disease137. Human peripheral blood leucocyte 
cultures inoculated with DV, produce CF139,140. CF is 
DV-specific, therefore, can be used for developing a 
diagnostic kit.
Suppressor T cells 
 For the first time microbe-induced suppressor 
cells or T cells cascade was shown in DV-infected 
mice117,118,120,123 which was subsequently confirmed in 
a large number of viruses138. DV-specific suppressor T 
cell (TS) cascade has three sequential subpopulations 
of TS1, TS2, TS3 cells (Table III) and their secretary 
soluble suppressor cytokines (SF1, SF2, SF3). DV-
infected macrophage transmits the signal to recruit 
TS1 cells, which secrete a suppressor cytokine, 
SF1. SF1 is composed of two polypeptide chains141, 
the alpha-chain binds to the beta-chain of the SF 
receptor (SF-R) present on macrophage142 while the 
beta-chain of SF1 binds to H-2A determinants on 
macrophage143, 144. SF1 is internalized by live syngeneic 
macrophage, processed and binds to H-2K antigen and 
is transported to a site other than SF-R on macrophage 
membrane for recruitment of TS2 cells145 (Table IV). 
TS2 produce a prostaglandin-like suppressor cytokine 
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(SF2). Live syngeneic macrophage transmits the SF2 
signal to recruit a third subpopulation of TS3, which 
suppresses humoral immune response in an antigen-
specific and genetically restricted manner118-120,123. 
DV-induced suppressor pathway suppresses antigen-
specific antibody production (immunosuppression to 
homologous antigen). Thus, suppression of neutralizing 
antibody would delay elimination of DV from the body 
causing pathological lesions123,125. In another study 
also suppressor T cell activity in dengue type 3 virus 
infected mice has been shown124. 
Macrophage & macrophage-like cells
 Macrophages are the primary component of the 
host innate immune system and provide first line of 
defence against viral infections. But in dengue viral 
infection, the macrophages play multiple paradoxical 
roles (Table IV), sometimes these help in eradicating 
the virus, while sometimes these actually increase 
its replication within the host158. On one hand, 
macrophages are the main cells which replicate dengue 
virus in man, mouse and monkey128 and the presence of 
macrophages is obligatory for the transmission of DV-
specific suppressor signal from the first subpopulation 
of suppressor T cells (TSl) to the second subpopulation, 
TS2123. On the other hand, macrophages are responsible 
for processing and presentation of DV antigen to B 
lymphocytes leading to their clonal expansion and 
immune response107,108. Further, it has been observed 
that DV induces generation of follicular helper T cells 
(ThF) in mice which secrete a helper cytokine (HF) 
which enhances clonal expansion of B lymphocytes in 
an antigen-specific and H-2 restricted manner112,149. The 
DV- induced CF kills H2-A negative macrophages111 by 
causing calcium influx, whereas it induces H2-A positive 
macrophages to produce a cytotoxin - CF2 which 
acts synergistically with CF150. CF-2 is a biologically 
active protein and causes various immunopathological 
effects including increased vascular permeability and 
damage to the blood brain barrier132,152,159,160. It has 
also been demonstrated that CF-2 induces production 
of NO2- in the spleen cells of mice thus mediating its 
cytotoxic effect on target cells155. This might be also 
one possible important trigger for switch from DF 
to DHF/DSS. In addition, in response to variety of 
stimuli, including viral infections, macrophages release 
migration inhibitory factor (MIF), which is a hormone 
released by different cells in many tissues in response 
to a variety of stimuli161. Macrophages also secrete a 
number of cytokines in viral infections, including DV 
infection158.
Cerebral oedema/encephalopathy during DV infection 
 Earliest reference to involvement of brain in dengue 
disease was encephalopathy or cerebral oedema, which 
was rare162. Therefore, the mechanism of cerebral 
oedema was studied in mouse model. A breakdown 
of the blood-brain barrier occurs in mice inoculated 
intracerebrally or intraperitoneally with DV 2 resulting 
in leakage of protein-bound Evans blue dye and 51Cr-
labelled erythrocytes into the brain tissue. Similar 
breakdown of the blood-brain barrier also occurred in 
mice inoculated intravenously with CF and CF2; the 
damage is dose-dependent and the vascular integrity 
is restored during the 3 h period after inoculation. 
Treatment of mice with antihistamine drugs, blocking 
H1 or H2 receptors, decreases the DV2-induced protein 
leakage. Pretreatment with CF-specific or DV2-specific 
antiserum inhibits protein leakage. Thus CF/CF2-
mediated breakdown of the blood-brain barrier leads to 
cerebral oedema during DV infection112,132,136,163.
Table IV. Macrophage functions in dengue virus infection in mice
Function Mechanisms References
DV-antigen presentation Induction and clonal expansion of DV-specific B cells 107-110
Transmission of suppressor signals Live macrophage internalize, process and externalize SF1 to present to 
naïve T cell by cell-cell contact to recruit TS2 cells
119, 120, 141-
143, 145, 146
Live macrophage internalize, process and externalize SF2 to present to 
naïve T cell by cell-cell contact to recruit TS3 cells
118, 147, 148
Transmission of T helper factor signals Live macrophage internalize, process and externalize HF to present help 
to naïve B cell by cell-cell contact to produce DV-antibody
112, 116, 149
Production of cytotoxin Amplification of the functions of CF. Increase capillary permeability, 
kill a subpopulation of macrophage and CD4 T cells
150-152
Production of nitric oxide Increases vascular leakage, cell apoptosis, inhibits virus replication, 
role in pathogenesis
153-157
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Capillary leakage in DV infection 
 One of the cardinal features of severe dengue is 
capillary leakage resulting into accumulation of fluids 
in various body cavities. Therefore, experiments 
were conducted to find out the mechanism of this 
phenomenon. It was observed that intraperitoneal 
inoculation of CF or CF2 in mice results in increased 
capillary permeability in a dose-dependent manner, 
as shown by leakage of intravenously injected 
radiolabelled iodine or Evans blue dye. Peak leakage 
occurs 30 min after inoculation of CF and the vascular 
integrity is restored by 2 h. The increase in capillary 
permeability is abrogated by pretreatment of mice 
with anti-CF antibodies, avil (H1 receptor blocker) or 
ranitidine (H2 receptor blocker)132,152. CF purified from 
the pooled sera of the DHF patients on intravenous 
inoculation into mice increased capillary permeability 
and damaged the blood-brain barrier136.
 CF and CF2 appear to be pathogenesis-related 
proteins, that can produce DHF-like pathological 
lesions in mice, such as capillary leakage, cerebral 
oedema, and blood leukocyte changes112,132,137,152,163. 
Pretreatment of mice with the anti-CF antibodies 
prevents pathological lesions produced by CF/CF2. 
Immunization of mice with CF protects them against 
subsequent challenge with CF, while challenge of 
such mice with a lethal intracerebral dose of DV 
prevents only the clinical symptoms not the death135. 
With the availability of endothelial cell monolayer 
models, extensive work has been done in recent 
times to understand the pathophysiology of vascular 
endothelium during dengue virus infection leading to 
plasma leakage as seen in severe dengue164-167.
Cardiac damage during DV infection 
 During the 1968 epidemic of DF at Kanpur, a 
few cases were suspected to have myocarditis22,23. 
Therefore, an effort was made to develop a mouse 
model to study it. Infant mice inoculated with DV 
show minimal histological cardiac injury in the form 
of cytoplasmic vacuolation of myocardium and foci 
of infiltration by mononuclear cells27. Subsequently, 
cardiac involvement in dengue disease was reported 
during 1996 epidemic of DHF at Delhi (Table I). 
Effect of DV infection on megakaryocytes and 
platelets 
 DV-2 inhibits in vitro megakaryopoiesis and 
induces apoptotic cell death in a subpopulation of early 
megakaryocytic progenitors which may contribute to 
thrombocytopoenia in dengue disease166. In another 
study it was shown that DV-2 may directly interact 
with and activate platelets and thus may be responsible 
for thrombocytopenia168. Significant ultrastructural 
changes in DV infected cells specially endomembrane 
re-organization and formation of autophagososmes 
have been shown using whole mount transmission 
electron microscopy169. These changes, taken together 
with a later study, that showed marked elongation 
of endothelial cell processes after transfection with 
the DV-E protein, provided early insights that the 
replication biology of the virus is coupled closely with 
the host cell physiology167.
Pathogenesis of DF/DHF
 Understanding the factors that are involved in 
the pathogenesis of DHF continues to be one of the 
most active areas of dengue research. It has been 
established that DHF is caused by a “Cytokine 
Tsunami” but despite extensive studies for over four 
decades, its genesis is still not fully understood. The 
mechanisms that have been considered to cause DHF 
include antibody-dependent enhancement (ADE)170, 
T cell response122,123,171, and a shift from Th-1 to Th-2 
response172. The combined effect of all of these is 
cytokine tsunami125 resulting in movement of body 
fluids in extravascular space. Various cytokines have 
been implicated in the immuno-pathogenesis of DF/
DHF as summarized in Table V. It has been suggested 
that in dengue a Th1 response is linked to recovery 
from infection while a Th2 type response leads to 
severe pathology and exacerbation of the disease172,182. 
The role of Th17 cells in dengue pathogenesis has 
been examined and warrants serious consideration 
by researchers183. CF/CF2 induces macrophage to 
produce free radicals, nitrite, reactive oxygen and 
peroxynitrite153,154,158,182,184,185. The free radicals, besides 
killing the target cells by apoptosis also directly 
upregulate production of pro-inflammatory cytokines; 
interleukin (IL-1), tumour necrosis factor (TNF)-alpha, 
IL-8, and hydrogen peroxide in macrophage. Oxidative 
stress develops from the onset of dengue infection. 
Plasma protein carbonylation, protein carbonylation to 
protein-bound sulphydryl group ratio are reported to 
predict DHF/DSS93,94. The change in relative levels of 
IL-12 and transforming growth factor (TGF)-beta shifts 
a Th1-dominant response to a Th2 biased response 
resulting in an exacerbation of dengue disease. The 
vascular permeability is increased due to combined 
effect cytokine tsunami, release of histamine, free 
radicals and the products of the complement pathway, 
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etc. Thus the key player appears to be CF/CF2, but the 
activity is regulated by CF-autoantibodies generated in 
patients with dengue disease186.
 The accompanying factors that have been 
discussed from time to time are dengue non-
structural protein of virus type 1 (NS1)-antibodies 
cross-reacting with vascular endothelium (a type of 
autoimmune phenomenon), immune complex disease, 
complement and its products, memory T cells, various 
soluble mediators including cytokines selection of 
virulent strains and virus virulence, etc.125,157,172,182,187. 
Further, DV has been shown to evade the innate 
immune mechanisms of the host by inhibiting both 
type I interferon (IFN) production and signaling in 
susceptible human cells, including dendritic cells 
(DCs). DV also encodes proteins that antagonize 
type I IFN signaling, including NS2A, NS4A, NS4B 
and NS5 by targeting different components of this 
signaling pathway, such as STATs. This contributes 
to the pathogenesis and host tropism of this virus188. 
Further, a critical role for invariant natural killer (iNK) 
T cells in mice189; altered plasma concentrations of 
vitamin D and mannose binding lectin190; shift from 
Th1 cytokine to Th2 cytokine expression; role of 
saliva of Ae. aegypti191; and intracellular changes 
in host proteins192 have been reported. Two loci on 
chromosomes 6 and 10 have been identified that are 
associated with susceptibility to DSS193. Classical and 
non-classical HLA alleles have been attributed to be 
related with disease severity in the host158,194,195. Other 
mechanisms that have been suggested are that DV 
utilizes calcium modulating cyclophilin-binding ligand 
to subvert the apoptotic process which in turn favoured 
efficient virus production196. A correlation of elevated 
lipopolysaccharide levels with disease severity has 
also been reported197.
 Still the exact cascade of mechanisms involved in 
dengue disease pathogenesis remains unexplained and 
lot more needs to be done. 
Establishment of mosquito cell line 
 A forerunner of mosquito cell line C6/C36 was 
established at Pune198 for the isolation of dengue 
viruses. This was the first time when mosquito cells 
were used as cell culture. 
Diagnosis of dengue virus infection
 Diagnosis of DV infection is routinely done 
by demonstration of anti DV IgM antibodies or by 
NS-1 antigen in patients’ serum depending upon day 
of illness using ELISA kits (prepared by National 
Institute of Virology, Pune) and commercial kits199. 
Molecular methods (reverse transcriptase PCR) are 
being increasingly used in diagnosis of DV infection. 
A single tube nested PCR for detection and serotyping 
of DV was developed and used for detection of co-
infection by two viruses200. DV isolation in tissue 
culture cells and its sequencing is also being done175. 
Treatment of dengue virus infection 
 The management of dengue virus infection is 
essentially supportive and symptomatic. No specific 
treatment is available. However, there are Indian studies 
which have contributed in terms of better management 
of DHF/DSS. A rapid response to platelet and fresh 
frozen plasma (FFP) transfusion is reported in a study201. 
Anti-D has been used in children with DHF and severe 
refractory thrombocytopenia202. In experimental study 
pre-feeding mice with trivalent chromium picolinate 
(CrP) in drinking water could abolish the adverse 
effects of DV infection on most of the haematological 
parameters203. Hippophae rhamnoides (Seabuckthorn, 
SBT) leaf extract has been shown to have a significant 
anti-dengue activity204.
Vaccine for dengue virus
 Dengue vaccines have been under development 
since the 1940s, but a tetravalent vaccine which 
simultaneously provides long-term protection against 
all DV serotypes is round the corner205. 
Table V. Serum cytokine levels in the pathogenesis of dengue 
Cytokine Levels in 
DF
Levels in 
DHF
References
IL-1β - - 173
IL-2 ↑↑ ↑ 139
IL-4 ↓ ↑↑ 139, 174, 175
IL-6 ↑ ↑↑ 139, 173, 176
IL-8 ↑↑ ↑↑ 173, 176, 177
IL-10 ↓ ↑↑ 139, 173
IL-12 ↑↑ ↓ 173, 178
IL-13 ↓ ↑↑ 179
IL-18 ↑ ↑↑ 179
TNF-α ↑↑ ↑↑ 139, 173, 175, 176, 180
IFN-γ ↑↑ ↑ 139, 174, 175, 176, 180
TGF- β ↓ ↑↑ 181
Human CF ↑ ↑↑ 136, 139
IL, interleukin; TNF, tumour necrosis factor; IFN, interferon; 
TGF, transforming growth factor
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Table VI*. Dengue antigens developed with potential for vaccine purposes
Expression Antigen Antigen design/ salient findings Ref
Escherichia 
coli
DV 4 envelope 
domain III
Overexpressed in the form of insoluble inclusion bodies 207
DV 4 envelope 
domain III
Molecular interaction with heparan sulphate, refolded and purified to homogeneity 208
rDen 4 EDIII Highly immunogenic with compatible adjuvants 209
r-D2EIII Purified from inclusion bodies; protected cells against DV-2 challenge 210
r-DME-G Multiepitope antigen containing IgG-specific epitopes 211
r-DME-M Multiepitope antigen containing IgM-specific epitopes; used to develop a rapid  
strip assay
212
r-HD Domain II of M. tuberculosis Hsp70 fused to r-DME-G; enhanced immunogenicity 
of r-DME-G did not elicit DENV neutralizing antibodies
213
r-EDIII-4/2 Fusion of envelope domain IIIs of DENV-4 and DENV-2; elicit neutralizing 
antibodies to DENV-4 and DENV-2
214
r-EDIII-T Envelope domain IIIs of the four types linked in a tandem array; detects anti-DV  
IgM & IgG antibodies, sensitivity is enhanced by coating biotinylated r-EDIII-T  
on streptavidin plates
215, 216
b-EDIII-T In vivo biotinylated version of r-EDIII-T antigen 217
Pichia 
pastoris
Den2E-HBsAg A hybrid antigen containing the ectodomain of DV-2 E (aa 1-395) fused to  
hepatitis B surface antigen
218
Den2E-HBsAg Exist as virus like particles and acts as a bivalent immunogen 219
EDIII-2 Antigen corresponding to DV-2 envelope domain III; expressed in methanol- 
induced Pichia cells; elicit DV-2-specific neutralizing antibodies
220
sEDIII-2 Secrets recombinant DV-2 envelope domain III 221
r-EDIII-T A tetravalent envelope antigen domain IIIs linked in a tandem array; unlike its 
E. coli-expressed counterpart, the Pichia-expressed tetravalent antigen elicited 
neutralizing antibodies specific to all four DENV serotypes
206
Adenovirus DENV-2 E Last 31 aa of DV-2 prM + the first 395 aa of E encoded by an adenovirus vector; 
elicit DV-2 specific neutralizing antibodies
222
DENV-2 EDIII Monovalent DV-2 EDIII gene expressed using plasmid and adenoviral vectors;  
elicit DV-2-specific neutralizing antibodies and T cell responses
223
EDIII-4/2 Fusion of envelope domain IIIs of DV-4 and DV-2, expressed using plasmid and 
adenoviral vectors elicit neutralizing and T cell responses DV-2 and DV-4
224
EDIII-T The EDIII-based tetravalent antigen expressed using plasmid and adenoviral vectors; 
elicit neutralizing antibodies and T cell responses specific to four DV serotypes
225
*Modified from the Table provided by Dr S. Swaminathan and Dr Navin Khanna (personal communication)
r-D2EII, envelope domain III encoded by dengue virus type-2 (DENV-2); r-DME-G, dengue multiepitope antigen specific to IgG class 
of anti-dengue antibodies; r-DME-M, dengue multiepitope antigen specific to IgM class of anti-dengue antibodies; r-HD, fusion antigen 
comprising mycobacterial Hsp70 domain II fused in-frame to the r-DME-G antigen; r-EDIII-4/2, bivalent fusion antigen comprising 
envelope domain III of dengue virus type 4 linked in-frame to envelope domain III of DENV-2; r-EDIII-T, tetravalent fusion antigen 
comprising envelope domain IIIs corresponding to the four dengue virus types, linked in-frame in a tandem array; b-EDIII-T, r-EDIII-T 
antigen fused to a biotin acceptor peptide at its N-terminus (to permit in vivo biotinylation; Den2E-HBsAg, bivalent fusion antigen 
comprised of the first 395 amino acid (aa) residues of DENV-2 envelope linked to the 224 aa residue Hepatitis B virus surface antigen; 
EDIII-2 (or DENV-2 EDIII), envelope domain III encoded by DENV-2; sEDIII-2, secreted form of EDIII-2; DENV-2 E, envelope 
antigen (aa 1-395) encoded by DENV-2 
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 A tetravalent antigen was designed by splicing the 
EDIIIs of DV-1, DV-2, DV-3 and DV-4 using flexible 
pentaglycyl linkers. A synthetic gene encoding this 
tetravalent antigen was expressed in Pichia pastoris 
and purified to near homogeneity. This tetravalent 
antigen when injected into inbred BALB/c mice, 
elicited neutralizing antibodies specific to each of the 
four DVs in plaque reduction neutralization tests206. 
Efforts are underway to present the tetravalent antigen 
on a chimeric VLP platform. Some promising dengue 
antigens have been developed using different systems 
(Table VI).
Recombinant dengue virus antigens 
 Several studies have contributed in terms of 
developing new reagents or technology for diagnostic 
purposes (Table VI). A recombinant DV3 envelope 
domain III (rDen 3 EDIII) protein has been produced 
in Escherichia coli for potential use in diagnosis210,226. 
A biotinylated chimeric dengue antigen to exploit the 
high affinity of biotin-streptavidin interaction to detect 
anti-dengue antibodies has been developed which 
incorporates the envelope domain III of all four DV 
serotypes216,217. Immunosensor has been established 
for label free and real time assay for the serological 
diagnosis of DV infection. Scope for development 
of biosensors for diagnosis was demonstrated227. The 
recombinant dengue multiepitope (rDME-M) protein 
specific to IgM in E. coli was produced in a 5-L 
fermentor for use in diagnostic purpose228.
Vector control
 Aedes aegypti is the commonest vector of DV 
in India, followed by Ae. albopictus. Larval indices 
indicate that Ae. aegypti is well established in peri-
urban areas and is beginning to displace Ae. albopictus. 
Water-holding containers, viz. plastic, metal drums and 
cement tanks facilitate breeding of Ae. aegypti229,230. 
Expansion in the risk area of diseases borne by it in 
the context of urbanization, transport development and 
changing habitats is a major concern231. 
 Vector control is known to be a good method for 
prevention of vector borne diseases. There are several 
reports from India which have demonstrated resistance 
of mosquito vector with anti larval substances like 
DDT and dieldrin but susceptibility to malathione is 
reported232. Temephos is relatively more effective in 
controlling Ae. aegypti, followed by fenthion, malathion 
and DDT233. Peridomestic thermal fogging reduced 
the resting and biting for the 3 days after treatment, 
whereas indoor fogging suppressed adult populations 
for 5 days234. 
 Plant based repellent against mosquito borne 
diseases235 have also been described. Flavonoid 
compounds derived from Poncirus trifoliata 
compounds have various activities against different 
life stages of Ae. aegypti239. Larvicidal and ovicidal 
activities of benzene, hexane, ethyl acetate, methanol 
and chloroform leaf extract of Eclipta alba have shown 
potential for controlling Ae. aegypti mosquito237. 
Hydrophobic nanosilica at 112.5 ppm is effective 
against mosquito species238. 
Assessment of public awareness on dengue virus 
infection
 Dengue is one of the major public health 
problems which can be controlled with active 
participation of the community. Need is to organize 
health education programmes about dengue disease 
to increase community knowledge and sensitize the 
community to participate in integrated vector control 
programmes229,239.
Conclusions
 Dengue disease continues to involve newer areas, 
newer populations and is increasing in magnitude, 
epidemic after epidemic. Every aspect of dengue viral 
infection continues to be a challenge; the pathogenesis 
of severe dengue disease is not known, no vaccine 
is yet available for protection and the vector control 
measures are inadequate. Dengue virus was isolated 
in India in 1944, but the scientific studies addressing 
various problems of dengue disease have been carried 
out at limited number of centres. Though clinical 
studies have reported on dengue disease in India, but 
these are largely based on diagnosis made by kits of 
doubtful specificity and sensitivity. A lot more remains 
to be achieved for creating an impact. 
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